Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5128MR)

This product GTTS-WQ5128MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5128MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12898MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ14591MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ5372MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ4493MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ4238MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ13016MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ7478MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ2539MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW